Nick C. Leasure

Learn More
NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to determine if trastuzumab plus radiation will reduce in-breast(More)
e16587 Background: Oncologists and managed care organizations are challenged with incorporating an ever-growing array of evidence-based chemotherapy regimens into treatment strategies, while maintaining high-quality, cost-effective care. Creating pathways can aid in overcoming this challenge by increasing workflow efficiency, encouraging adherence to(More)
588 Background: NSABP-B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER-2-positive DCIS. It compares whole breast irradiation (WBI) alone (Group [G] 1) with WBI given concurrently with trastuzumab (Group [G] 2) in women with HER-2 positive DCIS treated by lumpectomy. The primary aim is to determine(More)
Two cases of IgA multiple myeloma treated with syngeneic bone marrow transplant and a non-total body irradiation (TBI) conditioning regimen are reported. Both patients presented with stage III disease which responded to standard chemotherapeutic management. The myelo-ablative program for transplant consisted of busulfan and cyclophosphamide (Bu/Cy).(More)
  • 1